Literature DB >> 33269990

Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women.

Xiaomeng Ma1,2, Katherine Harripersaud3, Kumi Smith3, Christopher K Fairley4,5, Huachun Zou6, Zhuoru Zou1, Yueyun Wang7, Guihua Zhuang1, Lei Zhang1,4,5.   

Abstract

Human papillomavirus (HPV) infection is common in women and also the main cause of cervical cancer. Based on a dynamic compartmental model, we aimed to evaluate the population impact and cost-effectiveness of strategies that combined cervical cancer screening and HPV schoolgirl vaccination for Chinese women. The effectiveness of interventions was assessed by comparing modeled scenarios to the status quo, where a 3-y cervical cancer screening program remained at a 20% coverage and without a universal HPV vaccination program. Our study demonstrated that increasing screening coverage from 20% to 50% would reduce the high-risk HPV (HR-HPV) prevalence to 5.4%, whereas a universal schoolgirl vaccination program using the quadrivalent vaccine (qHPV) with a coverage of 50% would reduce the prevalence to 2.9% by 2069. Scaling-up the cervical screening coverage to 50% will prevent 16,012 (95% CI: 8,791 to 25,913) Disability-Adjusted Life-Years (DALYs) per year, with an incremental cost-effectiveness ratio (ICER) of US$ 10,958 (95% CI: $169 to $26,973)/DALY prevented. At the current qHPV price, vaccinating 50% of school girls will prevent 13,854 (95% CI: 8,355 to 20,776) DALYs/year, but the corresponding incremental cost-effectiveness ratio (ICER, US$ 83,043, 95% CI: $52,234 to $138,025) exceeds cost-effectiveness threshold (i.e., 3 times GDP per-capita of China: $30,792). The qHPV vaccine requires at least a 50% price reduction to be cost-effective. Vaccinating schoolgirls will result in a large population health benefit in the long term, but such a universal HPV vaccination program can only be cost-effective with a substantial price reduction.

Entities:  

Keywords:  Human papillomavirus; cervical cancer; cost-effectiveness; economic evaluation; intervention; screening; vaccination

Year:  2020        PMID: 33269990      PMCID: PMC8018426          DOI: 10.1080/21645515.2020.1832835

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  43 in total

1.  [Incidence and mortality of cervical cancer in China, 2014].

Authors:  X Y Gu; R S Zheng; K X Sun; S W Zhang; H M Zeng; X N Zou; W Q Chen; J He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2018-04-23

2.  Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis.

Authors:  Xiaomeng Ma; Qian Wang; Jason J Ong; Christopher K Fairley; Shu Su; Peng Peng; Jun Jing; Linhong Wang; Nyi Nyi Soe; Feng Cheng; Lei Zhang
Journal:  Sex Transm Infect       Date:  2018-05-24       Impact factor: 3.519

3.  Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.

Authors:  Jie-Bin Lew; Kate T Simms; Megan A Smith; Michaela Hall; Yoon-Jung Kang; Xiang Ming Xu; Michael Caruana; Louiza Sofia Velentzis; Tracey Bessell; Marion Saville; Ian Hammond; Karen Canfell
Journal:  Lancet Public Health       Date:  2017-02-07

Review 4.  Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.

Authors:  Nyi Nyi Soe; Jason J Ong; Xiaomeng Ma; Christopher K Fairley; Phyu Mon Latt; Jun Jing; Feng Cheng; Lei Zhang
Journal:  Hum Vaccin Immunother       Date:  2018-09-11       Impact factor: 3.452

5.  Human papillomavirus infection and associated factors for cervical intraepithelial neoplasia in women living with HIV in China: a cross-sectional study.

Authors:  Qian Wang; Xiaomeng Ma; Xiaosong Zhang; Jason J Ong; Jun Jing; Lei Zhang; Lin-Hong Wang
Journal:  Sex Transm Infect       Date:  2018-10-18       Impact factor: 3.519

6.  Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study.

Authors:  Helen C Johnson; Erin I Lafferty; Rosalind M Eggo; Karly Louie; Kate Soldan; Jo Waller; W John Edmunds
Journal:  Lancet Public Health       Date:  2017-12-19

7.  Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003-2014.

Authors:  Meg Watson; Vicki Benard; Elaine W Flagg
Journal:  Prev Med Rep       Date:  2018-02-02

8.  Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.

Authors:  Horace C W Choi; Mark Jit; Gabriel M Leung; Kwok-Leung Tsui; Joseph T Wu
Journal:  BMC Med       Date:  2018-08-17       Impact factor: 8.775

Review 9.  Awareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studies.

Authors:  Yanru Zhang; Ying Wang; Li Liu; Yunzhou Fan; Zhihua Liu; Yueyun Wang; Shaofa Nie
Journal:  BMC Public Health       Date:  2016-03-03       Impact factor: 3.295

View more
  2 in total

1.  Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies.

Authors:  Wenchuan Shi; Xiaoli Cheng; Haitao Wang; Xiao Zang; Tingting Chen
Journal:  BMJ Open       Date:  2021-12-08       Impact factor: 2.692

2.  The Lifetime Cost Estimation of Human Papillomavirus-related Diseases in China: A Modeling Study.

Authors:  Wenpei Ding; Yue Ma; Chao Ma; Daniel C Malone; Aixia Ma; Wenxi Tang; Lei Si
Journal:  J Transl Int Med       Date:  2021-09-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.